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Background: Data from recent randomised trials of antithrombotic treatment for ACS have highlighted the influence of bleeding complications on 
outcome. Little is known about the prevalence of major bleeding complications in NSTE-ACS in clinical practice.
Methods: Between October 2006 to October 2008, 21,582 consecutive patients with ACS were enrolled into the ACS-Registry of the Euro Heart 
Survey Programme to document treatment and hospital complications. We examined the impact of major bleeding complications (bleeding with 
drop of haemoglobin >5g/dl or hematocrit > 15%) on hospital outcome of NSTE-ACS.
Results: Of 12,850 patients with NSTE-ACS, 270 (2.1%) had major bleeding complications. Independent determinants of major bleeding were age, 
gender, invasive approach, renal failure, Killip-Class, number of antithrombotic agents. Main bleeding site was vascular access in those patients 
undergoing invasive treatment. Hospital mortality was significantly higher in patients with major bleeding even after correction for differences in 
baseline-characteristics, kind of NSTE-ACS and antithrombotic treatment (OR 4.22, 95% CI 2.69-6.61).
Conclusion: Determinants of major bleeding complications in NSTE-ACS were increasing age, female gender, renal failure, the number of 
antithrombotic agents as well as invasive treatment strategy. Major bleeding complications were associated with 4-fold increased hospital mortality 
in clinical practice. 
Major bleeding
n=270
No major bleeding
n=12,580
p-value
Age [years] 75 69 < 0.01
Female Gender 47.0 % 36.4 % <0.01
Prior MI 32.3 % 29.6 % ns
Prior PCI 18.2 % 17.8 % ns
Prior Bypass 10.4 % 6.8 % <0.05
Prior Stroke 11.1 % 6.4 % <0.01
Diabetes mellitus 33.0 % 29.9 % ns
Renal Failure 16.7 % 7.9 % <0.01
PCI 60.2 % 42.6 % <0.01
GP IIb/IIIa 22.2 % 11.7 % <0.01
ASA 93.3 % 93.3% ns
Clopidogrel 79.3 % 80.8 % ns
LMW-Heparin 54.7 % 53.6 % ns
Unfr. Heparin 65.2 % 55.4 % <0.05
Hospital Mortality 11.1 % 3.1 % <0.01
